Low enhancing papillary renal cell carcinoma diagnosed by using dual energy computerized tomography: a case report and review of literature

Shaheen Alanee1*, Danuta I Dynda2, Patrick Hemmer3 and Bradley Schwartz1

Abstract

Background: Papillary renal cell carcinoma (pRCC) is a mixed group of tumors that constitutes about 15-20% of all renal cortical cancers. Strong enhancement on computerized tomography (CT) is a feature of clear cell, but not of pRCC making the differentiation of papillary tumors from benign cysts a diagnostic problem in some cases.

Case presentation: We report here a case of a female patient with pRCC that was initially diagnosed as a benign renal cyst. The patient is a 66 year old Caucasian female who initially presented with an ultrasound showing a 2.6 cm hypo-echoic lesion within the inferior pole of her left kidney. This was followed by a contrast enhanced computerized tomography that suggested the hypo-echoic lesion to be a hyper-attenuating benign renal cyst. Follow-up CT scan 4 months later demonstrated an increase in the size of the lesion to 3.2 cm with equivocal enhancement. A dual energy computerized tomography (DECT) showed the lesion to be a solid mass suspicious for renal cell carcinoma. A robotic partial nephrectomy revealed a papillary renal cell carcinoma with negative margins.

Conclusion: In this case report, we reviewed the literature on variations in enhancement of renal tumors and the possible role of dual energy CT scan in differentiating papillary tumors with low enhancement from benign kidney cystic lesions.

Keywords: Papillary renal cell carcinoma, Renal cyst, Dual energy computerized tomography
post contrast images. The lesion did not demonstrate significant wall thickening, septations, or mural nodules (Figure 1a). The patient then presented to our clinic for further management. Fortunately, a DECT scanner was recently installed at an affiliate hospital of the Southern Illinois University School of Medicine (St John’s Hospital - Springfield, IL), and the Radiology Department at St. John’s Hospital had communicated to us the possible benefit of DECT in renal tumors with equivocal enhancement characteristics. A shared decision was made with the patient to proceed with DECT imaging of the kidneys to further characterize her renal lesion. DECT was performed using Siemens 128 dual source dual energy computerized tomography machine, and Siemens Syno Via software was used to process the images. Iodine was noticed inside the lesion on DECT indicating tissue enhancement that is associated with solid tumors (Figure 1b). Recommendation was made to the patient for tumor removal and surgery was done robotically with no complications. Intraoperatively, the lesion was found to be a solid tumor emanating from the lower pole of the left kidney (see Additional file 1 for timeline).

Pathologic results

The final pathology demonstrated papillary renal cell carcinoma type I, approximately 3 cm in size, confined to the kidney with negative surgical margins (Figure 2).

Discussion

The incidence of RCC is rising worldwide, with RCC currently accounting for almost 3% of solid malignant tumors [6]. Obesity, and increasing utilization of imaging modalities are some of the factors contributing to the increase in RCC incidence [7-9]. CT scan is now recognized as the gold standard for evaluating RCC because it provides information about the tumor itself and its extension to surrounding structures. Multiple previous studies have attempted to differentiate clear cell carcinoma from other subtypes of the same disease using enhancement qualities, however, the only solid finding was that strong enhancement is a unique finding for clear cell RCC [10,11]. The diagnosis of papillary renal cell carcinoma is specifically problematic on CT since pRCC tend to enhance to a lesser extent than the normal renal cortex, and could be confused with more benign kidney lesions such as in the case of the patient we present in this report. The low vascularity of pRCC could be used to explain the low enhancement of these tumors making their differentiation from benign kidney cysts problematic. In fact, it was not unusual for pRCC to show no enhancement on angiography, when that modality was used to diagnose RCC before CT dominated the field. In addition, while clear cell tumors are generally large and have areas of necrosis, hemorrhage, and calcification, pRCC are generally smaller and homogeneous adding to the difficulty of differentiating them from fluid filled renal cysts.

Dual energy CT scan is a recent development in imaging technology that could change the way we image and follow-up on renal tumors [12]. DECT deals with many of the drawbacks of the contrast enhanced multiphase CT that we currently use to manage kidney tumors. DECT decreases the amount of radiation patients are exposed to due to the decrease in number of phases needed for a renal CT scan because it depends on one phase therefore omitting the need for pre-contrast images [13-16]. Furthermore, recent advances in DECT is allowing for synthesis of
monochromatic images from polychromatic data through spectral separation, which promises a more accurate measurement of renal tumors enhancement [17-19]. DECT works on simultaneous acquisition of two different energy spectra, and thus can acquire accurate information about tissue composition. DECT uses photoelectric energy emitted when an incident photon causes an electron to be emitted from atomic shells, an event common for elements with high atomic number like Calcium and Iodine, to identify different compounds. Therefore, DECT is able to differentiate between iodine and the surrounding soft tissue based on the difference in photoelectric energy between Iodine and the elements constituting human soft tissue (oxygen, carbon, nitrogen, and hydrogen) [20].

Iodine-specific dual-energy images on DECT allow for color coded display of the iodine particles inside renal lesions. With these types of images, one can differentiate a non-enhancing cyst from a solid-enhancing mass. Cysts would appear without any iodine signal because they are avascular, while solid vascular lesions demonstrate iodine as it accumulates in the volume being examined. The sensitivity of the technology for iodine signal compensates for the low vascularity of lesions like pRCC, and allow for their accurate characterization as solid masses [14,15,21-23]. Not only does DECT serve to differentiate renal cysts from solid masses in everyday patients, but it is also proving useful in special cases like patients with polycystic kidney disease (PCKD). In such patients, detecting solid growth enhancement in the kidney parenchyma that is replaced by a large number of cysts is very challenging. However, recent studies indicate that DECT can also be useful in detecting such growth in PCKD with reduced radiation dose; a reduction that is important considering that PCKD patients require serial imaging for follow-up for extended periods of time [24].

Along the same lines, DECT is beneficial in detecting residual cancer after thermal ablation of renal tumors. Changes, due to ablation and perinephric bleeding, may make it difficult to assess enhancement after ablative procedure, where enhancement is the sign of viable cancer. With iodine-specific dual-energy images, DECT could be a valuable technology in the urologist armamentarium to decide on the success of their therapeutic intervention. Park et al. in a recent paper, presented 47 patients treated with radiofrequency ablation (RFA) of renal tumor followed by DECT to predict tumor progression at RFA site, and he showed excellent diagnostic performance of DECT (sensitivity 100% and specificity 91.5%) for predicting local tumor progression. He then concluded that DECT allowed acceptable diagnostic performance after RFA with decreased patient radiation exposure.

Magnetic resonance imaging (MRI) and renal ultrasound are two other modalities routinely used in differentiating cystic from solid renal lesions. However, in comparison to MRI, DECT has a shorter acquisition time, is cheaper, and can be used in patients with pacemakers and other contraindications for MRI. DECT is also superior to ultrasound in that it is less operator dependent, and provides better tissue characterization.

Finally, there is a growing body of research that aims at using DECT to differentiate RCC subtypes, and to observe response to targeted therapy in metastatic RCC. These applications are based on using Iodine as a biomarker that provides additional information on tumor texture and helps

Figure 2 Hematoxylin and Eosin staining of the tumor tissue showing characteristic histology of papillary renal cell carcinoma. (inset: 100x magnification).
us appreciate changes in tumor tissue as it responds to tyrosine kinase therapy [13,25].

**Conclusion**

DECT, if validated in clinical practice, could save patients multiple testing to differentiate between benign renal lesions and solid masses with low enhancement that could be aggressive and deadly. Future applications of this technology beyond diagnosis are being developed, and may greatly enhance the value in DECT as an imaging tool in managing patients with renal tumors.

**Consent**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

**Additional file**

Additional file 1: Timeline.

**Abbreviations**

CT: Computerized tomography; DECT: Dual energy computerized tomography; PCKD: Polycystic kidney disease; pRCC: Papillary renal cell carcinoma; RCC: Renal cell carcinoma; RFA: Radiofrequency ablation.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

SA, DD, PH, BS were all instrumental in the creation of this manuscript, from extensive literature review, collection of CT and pathologic figures, obtaining patient consent, drafting and critically revising several drafts of the manuscript. All authors have read and approved the final manuscript.

**Author details**

1. Southern Illinois University School of Medicine, Division of Urology, 301 N Eighth St - St John Pavilion, PO Box 19665, 62794-9665 Springfield, IL, USA.
2. Center for Clinical Research/Division of Urology, Southern Illinois University School of Medicine, 301 N Eighth St - St John’s Pavilion, PO Box 19665, 62794-9665 Springfield, IL, USA.
3. Laboratory Medical Director, Saint John’s Hospital, 800 East Carpenter Street, 62769 Springfield, IL, USA.

**Received:** 13 October 2014  **Accepted:** 11 December 2014  **Published:** 19 December 2014

**References**

1. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophob) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. *Am J Surg Pathol* 1997, 21(6):621–635.
2. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol* 1997, 10(6):537–544.
3. Amin MB, Tamboli P, Pavlidis J, Strickler H, de-Peralta Venturina M, Deshpande A, Memon M. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol* 2002, 26(3):281–291.
4. Reuter VE, Presti JC. Contemporary approach to the classification of renal epithelial tumors. *Semin Oncol* 2000, 27(1):124–137.
5. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Blouin AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. *Hum Pathol* 2001, 32(6):590–595.
6. Ljungberg B, Campbell SC, Cho HY, Cho HY, Jacqmund D, Lee JE, Weikert S, Kiemeyer LA. The epidemiology of renal cell carcinoma. *Eur Urol* 2011, 60(4):615–621.
7. Leslie JA, Prhoda T, Thompson IM. Serendipitous papillary renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. *Urol Oncol* 2003, 21(3):39–44.
8. Verhoest G, Veillard D, Galluff F, De La Taille A, Salomon M, Abbou CC, Valeri A, Lechevalier E, Descotes JL, Lang H, Jacqmund D, Tostain J, Cindolo L, Ficara V, Artibani W, Schips L, Zugeuner R, Mulders PF, Meijer A, Patard JJ. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. *Eur Urol* 2007, 51(5):1296–1304, discussion 1304–1305.
9. Tacconnel X, Valeri A, Descotes JL, Morin V, Stridel E, Drocourt L, Joulivin V, Bocquerez P, Coulange C, Rambeaud JJ, Fournier G, Mejean A, Oncology Committee of the Association Française d’Urologie. Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. *Eur Urol* 2007, 51(4):980–987.
10. Bata P, Gyebrinar J, Tamoki DL, Tamoki AD, Kekesi D, Szendroi A, Fejer B, Szasz AM, Nyirady P, Karlinger H, Berczi V. Clear cell renal cell carcinoma and papillary renal cell carcinoma: differentiation of distinct histological types with multiphase CT. *Diagn Interv Radiol* 2013, 19(5):387–392.
11. Kim JK, Kim TK, Ahn HJ, Kim CS, Kim KS, Cho KS. Differentiation of subtypes of renal cell carcinoma on helical CT scans. *AJR Am J Roentgenol* 2002, 178(6):1499–1506.
12. Kang SK, Chandarana H. Contemporary imaging of the renal mass. *Urol Clin North Am* 2012, 39(2):151–170.
13. Chandarana H, Meigbow AJ, Cohen BA, Srivinasan R, Kim D, Leidecker C, Macari M. Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. *AJR Am J Roentgenol* 2011, 196(3):W693–W700.
14. Ascenti G, Mazzotti S, Mileto A, Rachiusa S, Donato R, Settineri N, Gaeta M. Dual-source dual-energy CT evaluation of complex cystic renal masses. *AJR Am J Roentgenol* 2012, 199(5):1026–1034.
15. Graser A, Becker CR, Staehler M, Clevert DA, Macari M, Amrten N, Nikolau K, Sommer W, Steif C, Reiser MF, Johnson TR. Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. *Invest Radiol* 2010, 45(7):399–405.
16. Ascenti G, Miletto A, Gaeta M, Blandino A, Mazzotti S, Scritchino E. Single-phase dual-energy CT urography in the evaluation of haematuria. *Clin Radiol* 2013, 68(2):e87–e94.
17. Yu L, Leng S, McCollough CH. Dual-energy CT-based monochromatic imaging. *AJR Am J Roentgenol* 2012, 199(5):Suppl:S59–S515.
18. Silva AC, Morse BS, Hara AK, Padov RG, Hongo N, Pavlicek W. Dual-energy (spectral) CT: applications in abdominal imaging. *Radiographics* 2011, 31(4):1031–1046, discussion 1047–1050.
19. Hartman R, Kawashima A, Takahashi N, Silva A, Vrtiska T, Leng S, Fletcher J, McCollough C. Applications of dual-energy CT in urologic imaging: an update. *Radiol Clin North Am* 2012, 50(2):191–205. v.
20. Mileto A, Marin D, Nelson RC, Ascenti G, Bull DT. Dual energy MDCT assessment of renal lesions: an overview. *Eur Radiol* 2014, 24(2):353–362.
21. Brown CL, Hartman RP, Dzubabak OP, Takahashi N, Kawashima A, McCollough CH, Brusewitz NR, Primak AM, Fletcher JG. Dual-energy CT iodine overlay technique for characterization of renal masses as cyst or solid: a phantom feasibility study. *Eur Radiol* 2009, 19(5):1299–1295.
22. Ascenti G, Mileto A, Krauss B, Gaeta M, Blandino A, Scritchino E, Settineri N, Mazzotti S. Distinguishing enhancing from nonenhancing renal masses with dual-source dual-energy CT: iodine quantification versus standard enhancement measurements. *Eur Radiol* 2013, 23(8):2288–2295.
23. Song KD, Kim CK, Park BK, Kim B. Utility of iodine overlay technique and virtual unenhanced images for the characterization of renal masses by dual-energy CT. *AJR Am J Roentgenol* 2011, 197(6):W1076–W1082.
24. Amrten N, Staehler M, Siegert S, Reiser MF, Graser A. Dual energy CT in patients with polycystic kidney disease. *Eur Radiol* 2012, 22(10):2125–2129.
25. Park J, Chandarana H, Macari M, Meigbow AJ. Dual-energy computed tomography applications in uroradiology. *Curr Urol Rep* 2012, 13(1):55–62.

Cite this article as: Alane et al.: Low enhancing papillary renal cell carcinoma diagnosed by using dual energy computerized tomography: a case report and review of literature. *BMC Urology* 2014, 14:102.